MedTrace Logo

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

NCT03414814 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-02-11

Study results available
· View outcomes & findings →

Summary

This is a single-arm, non-randomized multicentre phase 2 study in NSCLC patients with EGFR exon 20 insertion mutation, whose disease has progressed on standard chemotherapy.

Conditions

  • Locally Advanced or Metastatic NSCLC

Interventions

DRUG

Osimertinib 80 MG [Tagrisso]

Osimertinib 80mg once daily until disease progression

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Korean Cancer Study Group

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Tae Min Kim, MD, PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-04
Primary Completion
2021-08-03
Completion
2021-08-03

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03414814 on ClinicalTrials.gov